

---

# CNS SPECTRUMS

---

## CME Review Article

### **Treating to Target in Major Depressive Disorder: Response to Remission to Functional Recovery**

*This activity is provided by the Neuroscience Education Institute.*



*Additionally provided by the American Society for the Advancement of Pharmacotherapy.*



American Society for the Advancement of Pharmacotherapy  
Division 55, American Psychological Association

## CME Information

### Date of Release/Expiration

Released: December, 2015

CME credit expires: November, 2018

### Target Audience

This activity has been developed for prescribers specializing in psychiatry. All other health care providers interested in psychopharmacology are welcome for advanced study, especially primary care physicians, nurse practitioners, psychologists, and pharmacists.

### Learning Objectives

After completing this activity, you should be better able to:

- Make evidence-based treatment adjustments to address inadequate antidepressant response
- Implement evidence-based strategies for treatment-resistant depression
- Describe the molecular targets of novel antidepressant treatments

### Accreditation and Credit Designation Statements



The Neuroscience Education Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Neuroscience Education Institute designates this enduring material for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



American Society for the Advancement of Pharmacotherapy  
Division 55, American Psychological Association

The American Society for the Advancement of Pharmacotherapy (ASAP), Division 55 of the American Psychological Association, is approved by the American Psychological Association to sponsor continuing education for psychologists. ASAP maintains responsibility for this program and its content.

The American Society for the Advancement of Pharmacotherapy designates this program for 1.0 CE credit for psychologists.

### Instructions, Optional Posttest and CME Credit

The estimated time for completion of this activity is 60 minutes. There is no posttest fee nor fee for CME credits.

1. Read the article, evaluating the content presented
2. Complete the posttest and activity evaluation, available only online at [www.neiglobal.com/CME](http://www.neiglobal.com/CME) (under “CNS Spectrums”)
3. Print your certificate (if a score of 70% or more is achieved)

Questions? call 888-535-5600, or email [CustomerService@neiglobal.com](mailto:CustomerService@neiglobal.com)

### Peer Review

These materials have been peer reviewed by an MD to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

### Disclosures

It is the policy of the Neuroscience Education Institute to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. Therefore, all individuals in a position to influence or control content are required to disclose any financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Disclosed financial relationships with conflicts of interest have been reviewed by the Neuroscience Education Institute CME Advisory Board Chair and resolved.

### Authors

**Roger S. McIntyre, MD, FRCPC**, is a professor of psychiatry and pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, ON, Canada. Dr. McIntyre receives research

support from AstraZeneca, Bristol-Myers Squibb, Janssen-Ortho, Lilly, Lundbeck, Pfizer, Shire, and Sunovion; is a consultant/advisor to Allergan, AstraZeneca, Bristol-Myers Squibb, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, and Takeda; and is on the speakers bureaus of Allergan, AstraZeneca, Bristol-Myers Squibb, Janssen-Ortho, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Sunovion, and Takeda.

**Rodrigo B. Mansur, MD**, is a clinical research fellow in the Department of Psychiatry and Pharmacology, Mood Disorders Psychopharmacology Unit, University Health Network at the University of Toronto in Toronto, ON, Canada. Dr. Mansur receives research support from Lundbeck.

**Yena Lee** is a research assistant in the Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto in Toronto, ON, Canada. She has no financial relationships to disclose.

No writing assistance was utilized in the production of this article.

### ***CNS Spectrums Peer Review***

All CME articles are peer reviewed in accordance with the strict standards of *CNS Spectrums* and in accordance with requirements and recommendations of the International Committee of Medical Journal Editors. The Editorial policies of the journal *CNS Spectrums* and peer review of all articles that appear in the journal is managed independently by Cambridge University Press and no financial relationship exists between the CME provider and Cambridge for this service.

### ***Additional Peer Reviewer***

**Ronnie Gorman Swift, MD**, is a professor in and associate chairman of the department of psychiatry and behavioral sciences at New York Medical College in Valhalla, NY, and the chief of psychiatry and associate medical director at Metropolitan Hospital Center in New York, NY. Dr. Swift has no financial relationships to disclose.

The **Planning Committee** has no financial relationships to disclose.

### **Disclosure of Off-Label Use**

This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

### **Disclaimer**

Participants have an implied responsibility to use the newly acquired information from this activity to enhance patient outcomes and their own professional development. The information presented in this educational activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this educational activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. Primary references and full prescribing information should be consulted.

### **Cultural and Linguistic Competency**

A variety of resources addressing cultural and linguistic competency can be found at this link: [www.neiglobal.com/go/cmereg](http://www.neiglobal.com/go/cmereg)

### **Provider**

This activity is provided by NEI, the Neuroscience Education Institute.

Additionally provided by the American Society for the Advancement of Pharmacotherapy.

### **Acknowledgment of Financial Support**

This activity is supported by an unrestricted educational grant from Takeda Pharmaceuticals U.S.A., Inc.

# Treating to target in major depressive disorder: response to remission to functional recovery

Roger S. McIntyre,<sup>1,2\*</sup> Yena Lee,<sup>3</sup> and Rodrigo B. Mansur<sup>3</sup>

<sup>1</sup> Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

<sup>2</sup> Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada

<sup>3</sup> Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada

Treating to target in chronic diseases [e.g. Major Depressive Disorder (MDD)] fosters precision, consistency, and appropriateness of treatment selection and sequencing. Therapeutic target definitions/endpoints in MDD should satisfy patient-, provider-, and societal expectations. Functional recovery in depression and return to both physical and mental health are the overarching therapeutic objectives. Treating to target in MDD implies multidimensional symptomatic remission, with a particular emphasis on cognitive function and aspects of positive mental health. Several atypical antipsychotic agents (i.e. brexpiprazole, aripiprazole, quetiapine) are FDA-approved as augmentation agents in MDD. Vortioxetine, duloxetine, and psychostimulants have evidence of independent, direct, and robust effects on cognitive function in MDD. Vortioxetine is the only agent that demonstrates efficacy across multiple cognitive domains in MDD associated with functional recovery. Measurement-based care, health information technology/systems, and integrated care models (e.g. medical homes) provide requisite tools and health environments for optimal health outcomes in MDD. Achieving remission in MDD does not equate to health. Return to positive mental health as well as full functioning provide the impetus to pivot away from traditional provider-defined outcomes toward an inclusive perspective involving patient- and society-defined outcomes (i.e. optimization of human capital). As in other chronic diseases, treating to target (e.g. cognitive function) further increases the probability of achieving optimal health outcomes.

Received 28 August 2015; Accepted 19 October 2015

**Key words:** antidepressant, cognition, depression, target, treatment resistant.

## Introduction

The most recent data from the Global Burden of Disease Study (2013) concluded that Major Depressive Disorder (MDD) is the second leading cause of disability globally.<sup>1</sup> The human capital costs attributable to MDD are largely due to impairment in role function.<sup>2</sup> Cost-of-illness studies as well as “workplace depression” studies provide replicated and robust evidence of tremendous personal and societal costs attributable to MDD.<sup>3,4</sup> Macroeconomic theories (e.g. the Solow–Swan model) have described the correlation between technology, productivity, and employment opportunity. Historically, a positive correlation has existed between all 3 aforementioned variables.<sup>5</sup>

The current digital revolution (i.e. as evidenced by 3D printing and automation) has, however, created a polarized workforce wherein economic/vocational opportunities are differentially available for those individuals with the highest skillsets and educational attainment [e.g. sciences, technology, engineering, maths (STEM)]. Consequently, advances in technology are increasing productivity (in some sectors) but are not increasing overall workplace employment opportunities. The foregoing description of the global economic environment has tremendous implications for MDD: a multidimensional syndrome that manifests (or has prodromal stages) early in life (i.e. interfering with educational attainment). Moreover, MDD often pursues a recurrent, chronic, and/or lifelong course, debasing human capital throughout the illness trajectory.<sup>6–8</sup> Consequently, the projected human and economic costs attributable to MDD and other mental/brain disorders are projected to rise.<sup>1</sup> A derivative of the foregoing set of observations is that, at the individual patient level, there is an urgent need to refine therapeutic objectives to achieve the desired health

\* Address for correspondence: Dr. Roger S. McIntyre, MD, FRCPC, Professor of Psychiatry and Pharmacology, University of Toronto, Head, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8.

(Email: roger.mcintyre@uhn.ca)

This activity is supported by an unrestricted educational grant from Takeda Pharmaceuticals U.S.A., Inc.

outcomes defined from the perspectives of the patient, the provider, and the society.

For much of the last two decades, the importance of and rationale for achieving response to treatment have been convincingly presented both conceptually and empirically.<sup>9,10</sup> Subsequently, it was determined that the presence of subsyndromal depressive symptoms was associated with adverse patient-reported outcomes (i.e. decreased quality of life, function) as well as unfavorable illness course (e.g. increased risk for recurrence and healthcare utilization).<sup>11,12</sup> A clarion call for “remission,” which denotes the full abatement of depressive symptoms, was subsequently issued. The elimination of depressive symptoms has been highly associated with a more favorable illness trajectory and a reduction in illness-related measures.<sup>13,14</sup>

Notwithstanding the emphasis on remission, a substantial percentage of adults with MDD who achieve “full remission” continue to report unfavorable health outcomes. For example, many individuals with MDD “in remission” continue to be functionally impaired within the work domain, as well as in other interpersonal, social, and family domains.<sup>15,16</sup> Moreover, qualitative research in adults with MDD indicates that a prioritized therapeutic objective in MDD is the return of premorbid functioning, positive mental health, and vitality, over the elimination of depressive symptoms.<sup>17</sup> The disconnection between remission and full functional recovery in depression may be more pronounced in individuals in later stages of the illness trajectory and/or who have failed previous antidepressant agents.<sup>18</sup>

The overarching therapeutic objective in MDD is to achieve and sustain full functional recovery.<sup>19</sup> Insufficient outcomes achieved in MDD, even among those individuals who achieve symptomatic remission, have provided the impetus to identify and refine determinants of ongoing functional impairment. Several lines of evidence indicate that cognitive dysfunction in MDD is a critical determinant of health outcome, warranting assessment, measurement, and specific targeting.<sup>20</sup>

In this review, we will provide a synopsis of data supporting multiple modalities of treatment capable of facilitating symptomatic remission in MDD. We briefly summarize the literature supporting pharmacological, psychosocial, and neuromodulatory treatments, as well as complementary/alternative medicines (CAMs). Reference to investigational approaches is also briefly covered to the extent to which they are clinically relevant. This article is not intended to be a repository of all information related to this broad topic and instead is intended to be a synthetic review with clinical recommendations. The mechanisms hypothesized to mediate beneficial effects of treatment are also briefly reviewed.

## Methods

Electronic search of the PubMed/Medline database was conducted on August 14, 2015. “Major depressive

disorder” was cross-referenced with “response,” “remission,” “treatment resistance,” “mechanism of action,” “antipsychotics,” “antidepressants,” “combination,” and “augmentation.” Articles selected for inclusion in this review were those articles that were commensurate with the stated objectives of this article and informed by randomized-controlled trials or reviews. For mechanistic studies, decisions to include were based on method rigor. Article reference lists were also reviewed to further identify citations that were not identified in the initial search.

## Results

### *Treating to target: measuring symptoms, cognitive function, and general function*

The successful management of MDD begins with timely and accurate diagnosis (the rates of false positives and false negatives in diagnosing MDD remain alarmingly high).<sup>21</sup> A highly reproducible finding has been that duration of untreated illness is a powerful predictor of nonresponse to antidepressant treatment. After establishing the diagnosis, operationalizing remission is personalized to each individual as part of a collaborative approach.<sup>22</sup> Broadly speaking, full symptomatic remission is a guiding principle with a particular emphasis on cognitive and psychosocial function. Table 1 summarizes recommended tools for the screening, diagnosis, and rating MDD symptom severity, as well as recommended objective/subjective measures of cognitive and general function.

It is well established in medicine that supplementing clinical assessment with measurement-based devices provides opportunity for precision, consistency, and appropriate selection/sequencing of care (e.g. glycated hemoglobin).<sup>23,24</sup> Measurement-based care in MDD that is targeted and tailored to an individual has been demonstrated to improve health outcomes in MDD.<sup>23,24</sup>

### *Treatment modalities*

Incredulously, 6 decades after imipramine was introduced into psychiatry, the fundamental question as to what comprises a sufficient antidepressant trial duration remains a point of discussion/debate.<sup>25,26</sup> Available evidence indicates that changes in cognitive-emotional processing with antidepressants are apparent after a single dose of antidepressant treatment.<sup>27</sup> Notwithstanding, the question remains as to when a clinically significant benefit from an antidepressant would be expected to be observed. The preponderance of data indicates that response trajectories (i.e. using latent class analysis: a statistical approach that attempts to identify subgroups within a larger sample that exhibit different response trajectory) within heterogeneous samples of adults with MDD are highly variable between subpopulations.<sup>28</sup> A separate line of evidence suggests that some

TABLE 1. Tools for diagnosing MDD and measuring depressive symptom severity/ cognition/general function

Screening tools	Diagnostic tools	Symptom severity	Cognition	Patient-reported outcomes
CES-D	MINI	BDI	DSST	Sheehan Disability Scale
HADS	PHQ-9	CUDOS	Stroop Test	WHO Disability Assessment Schedule (WHO-DAS)
PHQ-2	PRIME-MD	HADS	TMT A/B	Short Form Health Survey (SF-36)
PHQ-9	PDSQ	HAM-D7/17	RAVLT	UPSA
Zung	SCID-CV	IDS	Simple Reaction Time Task	
		MADRS	Choice Reaction Time Test	
		PHQ-9	PDQ-20, PHQ-5	
		QIDS	CPFQ	

MDD, major depressive disorder; MINI, Mini International Neuropsychiatric Interview; PHQ, Patient Health Questionnaire; PRIME-MD, Primary Care Evaluation of Mental Disorders; PDSQ, Psychiatric Diagnostic Screening Questionnaire; SCID-CV, Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version; CES-D, Center for Epidemiological Studies—Depression Scale; HADS, Hospital Anxiety and Depression Scale; Zung SDS, Zung Self-Rating Depression Scale; BDI, Beck Depression Inventory; CUDOS, Clinically Useful Depression Outcome Scale; HAM-D, Hamilton Depression Rating Scale; IDS, Inventory of Depressive Symptomatology; MADRS, Montgomery–Åsberg Depression Rating Scale; QIDS, Quick Inventory of Depressive Symptomatology; DSST: Digit Symbol Substitution Test; TMT: Trail Making Test; RAVLT: Rey Auditory Verbal Learning Test; PDQ: Perceived Deficits Questionnaire; CPFQ: Cognitive and Physical Functioning Questionnaire; UPSA: University of California San Diego Performance-Based Skills Assessment.

Adapted from: Gelenberg AJ. *J Clin Psychiatry* 2010;71(Suppl E1):e01.

MDD subpopulations exhibit robust improvements within 1–3 weeks of treatment commencement, while others have a slower velocity of symptom change across weeks of observation and/or manifest detectable symptom improvement after 4 weeks of treatment.<sup>25,28</sup> Indeed, a sizeable subpopulation exhibits no response at all, and an underemphasized subpopulation exhibits symptomatic worsening with antidepressant treatment.

Notwithstanding, a “best fit” trajectory across MDD subpopulations indicates that symptomatic improvement within 2–3 weeks of treatment assignment has modest positive prediction of achieving response/remission upon completion of the acute phase (i.e. 6–8 weeks). A more robust negative prediction, however, is identified among individuals with minimal symptomatic improvement within 2–3 weeks, inviting the need for treatment intensity optimization. From a clinical perspective, it is not practical to expect an individual with MDD who is minimally responsive to treatment to continue with the index treatment intensity beyond 2–4 weeks. Integrating best evidence with pragmatism provides the rationale for recommending an intervention (i.e. dose optimization) after approximately 2–4 weeks of treatment if insufficient outcome is observed (i.e. equal to or greater than 20% reduction in symptoms).<sup>29</sup> Tacit to the foregoing recommendation is the requirement for quantitative and objective measurement to determine whether treatment targets have been achieved.

In addition to ongoing questions as to optimal treatment duration, there is no compelling evidence that any particular symptom-based “subtype” of MDD exhibits preferential response to any particular agent/class of treatments. For example, a recent subgroup analysis of the iSPOT-D trial (N = 1008), which was a randomized, open-label, practical clinical trial, reported

that depressive subtypes in individuals with MDD (e.g. melancholic, atypical, or anxious depression) did not predict remission or change in depressive symptoms after acute antidepressant therapy (i.e. escitalopram, sertraline, or extended-release venlafaxine).<sup>30</sup>

Predicting antidepressant response (or nonresponse) with biomarkers/biosignatures remains an area of particular interest, given insufficient clinical phenotypes for prediction. For example, the iSPOT-D trial reported that single-nucleotide polymorphism at the ABCB1 gene was a significant predictor of remission and side effects in individuals with MDD with or without cognitive impairment. For example, individuals homozygous for the common allele for rs10245483 responded significantly better to and had fewer side effects with escitalopram and sertraline. In comparison, individuals with MDD homozygous for the minor allele responded better to, and had fewer adverse events with, venlafaxine, particularly among those with impaired cognition.<sup>31</sup> Notwithstanding the foregoing promising finding, it does not seem likely that a single, or modest set, of biomarkers will be able to sufficiently predict a “trait” of response in a heterogeneous syndrome such as MDD. The future of psychiatry, it seems, is predicting response using both clinical and biological markers with dimensions/domains as the principle target of interest.

#### Pharmacological treatments

Individuals with MDD who remain symptomatic despite optimization of initial pharmacotherapy may be offered combined pharmacological treatments or may be switched to a mechanistically dissimilar pharmacological monotherapy.<sup>32</sup> Results from STAR\*D indicate that adults with MDD prefer augmentation if partial

improvement is achieved with the index agent.<sup>33</sup> Empirical support for add-on pharmacotherapy as a superior therapeutic avenue, when compared to switching to a separate antidepressant modality, is surprisingly modest. Notwithstanding, a randomized, direct comparison study of 101 individuals with MDD reported that aripiprazole augmentation was superior to antidepressant switching in individuals with current depressive episode despite adequate antidepressant dosage.<sup>34</sup> Similarly, post hoc analyses from the pivotal trials of aripiprazole as augmentation in MDD indicate that nonresponse to the index conventional antidepressant (or worsening on the index antidepressant) was highly associated with response and remission with aripiprazole augmentation.<sup>35,36</sup>

The U.S. Food and Drug Administration (FDA)-approved treatment strategies as augmentation are quetiapine, olanzapine-fluoxetine combination, aripiprazole, and more recently, brexpiprazole. Each of these agents has been comprehensively reviewed and published elsewhere.<sup>37-39</sup> Brexpiprazole is the newest atypical antipsychotic FDA-approved as an augmentation agent (also approved for adults with schizophrenia).<sup>40</sup> Brexpiprazole has a relatively lower intrinsic activity at the dopamine D2 receptor and significantly higher affinity at 5HT1A and 5HT2A, as well as several adrenergic receptors when compared to aripiprazole.<sup>40</sup> The differential affinity for the D2 receptor may explain the lower relative risk of akathisia observed with brexpiprazole relative to aripiprazole.<sup>40</sup> The optimal duration of add-on treatment with atypical agents is currently not known. In the absence of sufficient empirical basis to guide this decision, it seems prudent that individuals who are tolerating treatment and achieving therapeutic objectives should be offered ongoing therapy for a minimum of 6-12 months with ongoing reassessment and, in many cases, continuation of the treatment for an indefinite period of time.

Clinical and pharmaco-epidemiology data indicate that the combination of antidepressants is common and increasing in frequency when compared to a decade ago.<sup>41</sup> Moreover, individuals with MDD who are prescribed combination antidepressants are receiving the combination regimen for a longer period of time.<sup>41</sup> The combination of contemporary antidepressants is possible due to a greater safety profile when compared to the older classes of antidepressants [e.g. tricyclic antidepressants (TCAs), monoamine oxidase (MAO) inhibitors]. In addition to an acceptable safety profile, the combination of antidepressants provides the opportunity for “treating to target” (i.e. an individual insufficiently responsive to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) may be offered bupropion to target symptoms including, but not limited to, fatigue, apathy, and amotivation).<sup>42,43</sup> (Notwithstanding the

common practice of selecting monoamine-based antidepressants to abrogate symptoms across multiple dimensions, it is abundantly clear that monoamine antidepressants are not sufficient, and other cellular targets are needed. For example, targeting inflammatory systems in adults with MDD may be particularly effective in mitigating aspects of anhedonia).<sup>44</sup> Moreover, combining antidepressants may provide opportunity for the add-on agent to antidote adverse events that emerge with an index agent (e.g. mitigating sexual dysfunction with bupropion, reducing nausea with mirtazapine).<sup>42,45</sup>

Notwithstanding the common practice of co-prescribing antidepressants for longer trial durations, the evidentiary base supporting the practice is modest in size. For example, there is an absence of large, adequately powered, and replicated placebo-controlled trials documenting the efficacy of antidepressants as augmentation strategies in depression. Moreover, the co-prescription of 2 antidepressants at the initiation of therapy (i.e. rather than adjunctively administering the second agent following insufficient outcome with the index agent) with an aim to enhance and accelerate desired treatment outcomes has not produced consistent results.<sup>46,47</sup>

Pharmacological treatments other than conventional antidepressants, which may be considered as add-on strategies, are listed in Table 2. The evidentiary base for lithium and triiodothyronine is composed of studies wherein these 2 agents have typically been combined with TCAs or MAO inhibitors, with relatively fewer studies with SSRIs/SNRIs/multimodals (e.g. vortioxetine, vilazodone).<sup>29</sup> The evidence for psychostimulants has been mixed, with most studies failing to provide robust and consistent signal of efficacy in reducing depressive symptoms.<sup>48,49</sup> Similar to psychostimulants, modafinil has not been able to provide reproducible efficacy in MDD, but has demonstrated improvement in symptoms/dimensions of psychopathology highly relevant to patient function (e.g. fatigue, apathy, anhedonia, amotivation).<sup>50,51</sup> A recent meta-analysis (N = 6654) of all augmentation approaches in MDD

**TABLE 2. Pharmacological Agents**

Augmentation agents	Level of evidence
<b>Quetiapine</b>	Level I
<b>Olanzapine-fluoxetine</b>	Level I
<b>Aripiprazole</b>	Level I
<b>Brexpiprazole</b>	Level I
<b>Ziprasidone</b>	Level I
<b>Other add-on pharmacological agents</b>	Level of evidence
<b>Psychostimulants</b>	Level II
<b>Prampipexole</b>	Level II
<b>Modafinil</b>	Level II
<b>Lithium</b>	Level I–III
<b>Triiodothyronine (T3)</b>	Level I–III

reported that adjunctive quetiapine, aripiprazole, thyroid hormone, and lithium significantly reduced depressive symptoms in individuals with treatment-resistant MDD, with more robust improvements with add-on quetiapine or aripiprazole.<sup>52</sup>

#### *Psychosocial treatments*

Manual-based psychosocial treatments are unequivocally established as efficacious in the symptomatic treatment of MDD.<sup>53,54</sup> Psychosocial treatments are often preferred by many individuals with MDD and may be preferential as first-line treatment strategies in individuals with mild baseline severity. An additional rationale for prioritizing psychosocial treatments over pharmacological treatments in MDD of mild severity is the insufficient demonstration of efficacy in this subpopulation with antidepressants as part of placebo-controlled trials.<sup>55</sup>

Additional subpopulations that may differentially respond to psychosocial treatments include adults with MDD who are chronic and/or highly recurrent in course, individuals with comorbid mental disorders (e.g. personality disorders), and individuals with history of early childhood adversity.<sup>56</sup> Moreover, psychosocial treatments may be sequenced as add-on approaches to insufficient antidepressant treatment or considered as an initial treatment strategy with antidepressant therapy reserved for those insufficiently responsive to psychosocial treatment.<sup>57,58</sup> Many individuals, however, with moderate or severe subtypes of depression, as well as individuals with more cognitive problems as part of MDD, will require some degree of pharmacological treatment to engage and maintain participation in psychotherapy.

#### *Neuromodulatory treatments*

Electroconvulsive therapy (ECT) has consistently been identified as the most effective treatment strategy in treatment-resistant depression.<sup>59</sup> Notwithstanding, electroconvulsive therapy is highly stigmatized, not acceptable/accessible to most individuals, and is associated with problematic neurocognitive consequences.<sup>60</sup> Repetitive transcranial magnetic stimulation (rTMS) is a much more acceptable neuromodulatory treatment in MDD and is generally well tolerated and without prominent cognitive consequence.<sup>61-63</sup> Notwithstanding, rTMS appears to be inferior to ECT in its overall effect size in highly pharmacologically resistant patients.<sup>64</sup> The foregoing conclusion may, however, be related to rTMS parameters and delivery methods, which are being refined. Other neuromodulatory approaches include magnetic seizure therapy (MST), transcranial direct current stimulation (tDCS), and vagus nerve stimulation (VNS).<sup>65</sup>

#### *Complementary/alternative medicines (CAMs)*

The efficacy of complementary/alternative medicines to treat depressive symptoms is reviewed elsewhere.<sup>66</sup> The most compelling evidence exists for S-adenosyl methionine (SAME) and for L-methylfolate. For example, in a double-blind, randomized, placebo-controlled study, Papakostas *et al*<sup>67</sup> reported that adjunctive SAME was effective in reducing depressive symptoms in individuals with MDD with inadequate response to SSRIs. In a separate report, Papakostas *et al*<sup>68</sup> reported that adjunctive L-methylfolate was effective, safe, and well tolerated in the treatment of SSRI-resistant MDD. It has also been reported that a collection of biomarkers (e.g. genetics, peripheral proteins) relevant to metabolism and inflammation identifies a subset of adults with MDD differentially responsive to L-methylfolate.<sup>68</sup>

The data supporting omega-3 as a treatment strategy in MDD had been mixed, with more recent studies indicating that most individuals receiving omega-3 as augmentation may expect minimal to no benefit.<sup>69</sup> For example, a recent meta-analysis of 19 randomized controlled trials reported effect sizes ranging from -0.07 to 0.52 in individuals with MDD based on the type of omega-3 supplementation (e.g. EPA, DHA).<sup>69</sup>

#### *Investigational treatments*

The NMDA receptor antagonist and dissociative anesthetic ketamine has been studied as a treatment strategy in MDD (and bipolar depression) where it has demonstrated robust, fast-onset antidepressant effects. For instance, a recent pooled analysis reported a response rate of 67% (i.e.  $\geq 50\%$  improvement in Montgomery-Åsberg Depression Rating Scale score) with the administration of intravenous ketamine among individuals with treatment resistant depression.<sup>70</sup> Moreover, ketamine has also demonstrated anti-suicide effects; although they appear to be largely modified by reduction of depressive symptom severity, may also involve independent effects.<sup>71-73</sup> Ketamine's mechanism of action is hypothesized to involve the mammalian target of rapamycin (mTOR), which is a critical intracellular protein that mediates neuroplasticity and neurotrophic processes.<sup>74</sup>

Ketamine is available in several formulations, including oral, sublingual, intravenous, and intranasal. Methodological limitations affecting inferences that can be drawn from the interventional trials with ketamine in MDD are their short-term duration and the inadvertent unblinding via the induction of psychotomimetic effects. Although the use of a benzodiazepine as an act of reference agent in pivotal trials is reasonable, it would be preferred to include a reference agent that possesses psychotomimetic effects but no known antidepressant effects (e.g. mescaline). It needs also to be underscored that long-term data for



ketamine do not exist, and its use without consideration of its limitations, safety hazards, and need for surveillance is very strongly discouraged. Notwithstanding, the intranasal formulation of es-ketamine, which appears to be more potent at the NMDA-receptor system than its racemic mixture, appears to have a lower propensity to induce psychotomimetic effects and has been shown to be safe and effective in depression studies.<sup>75</sup>

The availability of ketamine has provided cause for introduction of a new typology “rapid-onset” and “delayed-onset” antidepressants. Although this typology provides for descriptive and axiomatic categorization, it is however imprecise, as available evidence indicates that immediate effects on emotional and cognitive processing offered by conventional antidepressants would suggest that active antidepressants are all “rapid-onset.” Nonetheless, clinically significant benefits, as have been obtained in more treatment-resistant populations with the NMDA-receptor antagonist ketamine (and nitrous oxide) in less than 3 days of treatment, suggest that some individuals may be offered sequential pharmacological therapy, wherein they receive a rapid-onset antidepressant for symptomatic improvement followed by transition to delayed-onset antidepressant.

#### *E-based treatment interventions*

Insufficient access to cost-effective and integrated healthcare, as well as modest resources in many jurisdictions for integrated mental health services, provide rationale for offering treatments via e-based platforms. For instance, recent evidence suggests that Web-based self-help intervention programs based on cognitive behavioral therapy or acceptance and commitment therapy may improve depression symptom outcomes in individuals with MDD.<sup>76–78</sup> None of these treatments has received FDA-approval in MDD, nor have any been adequately established as efficacious. Nonetheless, e-based treatments (e.g. Telehealth) are being actively studied with an aim to identify a subpopulation of adults with MDD who may respond to them.

#### **Targeting dimensions/domains: a focus on cognition**

The guiding principle of treating to target with remission as the symptomatic target increases the likelihood of, but does not guarantee, full functional recovery. Moreover, results from the STAR\*D trial indicate that workplace attendance and performance are dissociated from symptomatic remission beyond the first antidepressant treatment.<sup>79</sup> The empirical observation that depressive symptoms and general function are modestly correlated indicates that there are other determinants of functional outcome in MDD independent of core depressive symptoms.<sup>80</sup>

During the past decade, a concatenation of study results indicates that cognitive dysfunction is a critical

determinant of health outcome in adults with MDD who are otherwise in symptomatic remission.<sup>15,81,82</sup> It has been determined, for example, that functional outcomes among adults with MDD are associated with and/or mediated by cognitive dimension/domain disturbances to a greater extent than other domains in MDD (e.g. mood symptoms).<sup>20</sup>

For example, results from the International Mood Disorders Collaborative Project (IMDCP) indicate that, among adults with syndromal MDD who continue to be employed at least at a part-time level, their overall attendance and performance in the workplace is attributable to a greater extent to their self-rated cognitive abilities than it is to their overall depressive symptom severity.<sup>83</sup>

The notion that dimensions/domains within MDD have differential effects on the functional trajectory of an affected individual has several parallels in other areas of medicine. For example, it is well established that the subfractionated components of cholesterol [e.g. low density lipoprotein (LDL)] have very differential risk associations (i.e. end organ damage). In addition to treating to a predefined total cholesterol target, it is incumbent to also treat to target within one of the subdomains of cholesterol fractionation. It would not be acceptable for an individual to have a normal total cholesterol level for their age and gender (and other cardiovascular risk factors), yet have an abnormal LDL (or HDL, triglycerides) level. A parallel in MDD would be that in addition to aiming for a broad improvement in depressive symptoms [i.e. remission as defined according to the Hamilton Depression Rating Scale 17-item (HAM-D-17) or Montgomery-Åsberg Depression Rating Scale (MADRS)], treating to target also includes mitigation of cognitive dysfunction. In this context, cognitive dysfunction is broadly defined to include hot (e.g. cognitive emotional processing), cold (e.g. non-emotionally valenced cognitive processing), and social cognition (Table 3).<sup>84</sup>

**TABLE 3. Domains of cognition in MDD**

Cognition	Examples
<b>Hot cognition</b>	Rumination Catastrophic reactions Bias towards negative stimuli (internal/external) Anhedonia (e.g. anticipatory anhedonia)
<b>Cold cognition</b>	Executive function Information processing speed Learning and memory Attention/concentration
<b>Social cognition</b>	Theory of mind Mentalization

From McIntyre RS, Xiao HX, Syeda K, et al. *CNS Drugs*. 2015;29(7):577–589.

**TABLE 4. Antidepressants and psychotropic agents improve measures of cognition in individuals with MDD independent of improvements in measures of depressive symptom severity**

	Learning and memory	Attention/concentration	Executive function	Processing speed
<b>Vortioxetine</b>	1	1	1	1
<b>Duloxetine</b>	1			
<b>Lisdexamfetamine</b>			2	
<b>Other (e.g. SSRIs, SNRIs, bupropion)</b>	3	3	3	3
<b>Modafinil</b>	3	3	3	3
<b>Erythropoietin</b>	2	2	2	2

Independent effect indicated by a priori specification, cognition as primary; pathoanalysis; subgroup analysis in nonresponders and nonremitters.

Level 1: replicated placebo-controlled trial evidence with demonstration of independent effect; Level 2: single placebo-controlled trial evidence with demonstration of independent effect; Level 3: uncontrolled evidence (e.g. lacking placebo, case-series) with lack of demonstration of independent effect.

SNRIs, selective norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors.

Adapted from McIntyre RS, Xiao HX, Syeda K, et al. *CNS Drugs*. 2015;29(7):577–589.

The pertinence of cognitive dysfunction in psychiatry across the developmental trajectory has been underscored in the rationale for creating the Research Domain Criteria (RDoC).<sup>85,86</sup> The RDoC matrix provides a taxonomy wherein convergent psychopathologies across all mental disorders are presented as disturbances in emotional valence (i.e. positive and negative valence disturbances), general cognitive function, social cognition, and fear/arousal processes. Although the language of the RDoC is less familiar to most busy practitioners, the heuristic framework is highly familiar to patients, families, and care providers. For example, adults with MDD frequently ruminate about negative and maladaptive experiences. In addition, MDD is often characterized by profound anhedonia. Rumination and anhedonia would be examples of disturbances in negative valence and positive valence, respectively.

The foregoing has provided the impetus for determining whether psychotropic agents, as well as other treatment modalities, are capable of improving dimensions/domains of psychopathology within MDD (Table 4). As reviewed elsewhere, unequivocal evidence now indicates that the multimodal agent vortioxetine is capable of improving multiple domains of cognitive function (i.e. executive function, processing speed, attention, learning/memory) independent of its effect on core mood symptoms.<sup>87–89</sup> Replicated evidence also exists for duloxetine offering an independent and direct effect on the domain of learning and memory in adults with MDD.<sup>90,91</sup> A single published study has reported that the adjunctive use of the psychostimulant lisdexamfetamine offers significant benefits compared to placebo in improving self-reported measures of executive function<sup>92</sup>. Healthy controls, as well as clinical populations (e.g. schizophrenia, dementing disorders), exhibit beneficial effects across cognitive measures (e.g. working memory) with modafinil treatment.<sup>6</sup> Replicated evidence supporting modafinil's efficacy in hot or cold cognition in MDD is not available.<sup>84</sup>

## Summary and Conclusion

Major depressive disorder is a common, often severe, and lifelong disorder known to significantly debase human capital. Modifiable deficiencies that currently exist are timely and accurate diagnosis of MDD; access to coordinated, integrated, longitudinal, high-quality, and accountable care; insufficient concordance to chronic disease management principles (e.g. measurement-based care, inclusion of decision support); and the selection and sequencing of treatment modalities deemed effective in MDD.

It is now well established that for many adults with MDD, achieving the symptomatic target of remission is not associated with full functional recovery, nor is the improvement of symptoms alone commensurate with patient-prioritized therapeutic objectives.<sup>15</sup> It is now established that, like other mental disorders (e.g. schizophrenia, bipolar disorder), cognitive impairment in MDD is prevalent, pervasive, and a critical determinant of overall functional outcome.<sup>18</sup> As clinicians and patients treat to target, it will be critical to assess and measure not only conventional depressive symptoms, but also cognitive function and overall general psychosocial function.

The foregoing objective begins with the avoidance, to the extent possible, of concomitant agents that may adversely affect cognitive function (e.g. benzodiazepine) and to manage comorbid conditions that are known to interfere with cognitive function (e.g. substance use disorder, diabetes mellitus, hypothyroidism). Emerging evidence indicates that there are differences between antidepressants and their ability to mitigate cognitive function in MDD.<sup>88</sup> Moreover, several psychotropic agents as well as other pharmacological agents are being studied to determine whether they can be repurposed for psychiatric application that may have beneficial effects in the domain of cognition.<sup>93–95</sup>

Integrated care with a multidisciplinary team that involves focusing on physical health is also critical, as it is now well established that comorbid medical disorders are not only common in MDD, but affect health outcomes. For example, the American Heart Association now recognizes that having a mood disorder is a risk factor for having premature cardiovascular disease.<sup>96</sup> Moreover, obesity is associated with decreased treatment responses to conventional antidepressants, as well as less favorable functional outcomes.<sup>97-99</sup> A separate line of evidence also indicates that diabetes interferes with cognitive performance.<sup>100</sup> Taken together, optimal symptomatic, functional, and health outcomes are only likely to occur with contemporaneous attention given to both mental and physical health targets.

Trial evidence, as well as clinical experience, indicate that most individuals with MDD will not achieve functional recovery with pharmacological treatment alone.<sup>15</sup> Notwithstanding the availability of results from efficacy studies, and more recently meta-analyses that report on and compare between-agent efficacy in MDD, there is a paucity of “real-world” effectiveness studies in MDD as augmentation to determine the most appropriate and acceptable treatment to patients and clinicians. It is hoped that results from the Patient-Centered Outcomes Research Institute (PCORI) will provide instructive insights as to the appropriate “best next steps” when an initial antidepressant is unsuccessful.<sup>101</sup> Instead, pharmacological treatments should be integrated with general lifestyle improvement, risk factor modification, sleep hygiene, psychoeducation, and, in some cases, manual-based psychotherapy. The body of evidence supporting aerobic/resistance exercise has also become compelling, with a particular therapeutic offering in critical patient-reported outcomes (e.g. quality of life, function).<sup>102-106</sup>

Advances in medical technology (e.g. electronic health records, mobile phone technology, app-based health devices) provide a mechanism to digitalize and facilitate treating to target objectives in MDD.<sup>107</sup> Moreover, the digitalization of medical care provides a unique opportunity for patients and families to play an increasing and more central role in directing, monitoring, and measuring their chronic diseases. Treating to target is a collaborative, dynamic, and iterative process; the guiding principles of measurement-based care within the framework of chronic disease management and collocation of integrated care providers increase the probability of cost-effective, high-quality, accountable care.

## Disclosures

Roger McIntyre has the following disclosures: AstraZeneca, advisory board/researcher, consulting fees and speaker fees, no equity; BristolMyers Squibb, advisory board/researcher, consulting fees and speaker fees, no

equity; Eli Lilly, advisory board/researcher, consulting fees and speaker fees, no equity; Lundbeck, advisory board/researcher, consulting fees and speaker fees, no equity; Pfizer, advisory board/researcher, consulting fees and speaker fees, no equity; Merck, advisory board/researcher, consulting fees and speaker fees, no equity; Sunovion, advisory board/researcher, consulting fees and speaker fees, no equity; Otsuka, advisory board/researcher, consulting fees and speaker fees, no equity; Takeda, advisory board/researcher, consulting fees and speaker fees, no equity; Allergan, advisory board/researcher, consulting fees and speaker fees, no equity; Janssen-Ortho, researcher, speaker fees, no equity; Shire, Research, funding for research, no equity. Yena Lee has nothing to disclose. Rodrigo Mansur has the following disclosure: Lundbeck, researcher and other duties, fellowship funding.

## REFERENCES:

1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015; **386**(9995): 743-800.
2. Kessler RC. The costs of depression. *Psychiatr Clin North Am*. 2012; **35**(1): 1-14.
3. McIntyre RS, O'Donovan C. The human cost of not achieving full remission in depression. *Can J Psychiatry*. 2004; **49**(3 Suppl 1): 10S-16S.
4. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). *J Clin Psychiatry*. 2015; **76**(2): 155-162.
5. Cashin P, Sahay R. Internal migration, center-state grants, and economic growth in the states of India. *Staff Papers (International Monetary Fund)*. 1996; **43**(1): 123-171.
6. Sahakian BJ, Bruhl AB, Cook J, et al. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people. *Philos Trans R Soc Lond B Biol Sci*. 2015; **370**(1677): 20140214.
7. Collins PY, Insel TR, Chockalingam A, Daar A, Maddox YT. Grand challenges in global mental health: integration in research, policy, and practice. *PLoS Med*. 2013; **10**(4): e1001434.
8. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. *Nature*. 2011; **475**(7354): 27-30.
9. Prien RF, Carpenter LL, Kupfer DJ. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. *Arch Gen Psychiatry*. 1991; **48**(9): 796-800.
10. McIntyre RS, Fallu A, Konarski JZ. Measurable outcomes in psychiatric disorders: remission as a marker of wellness. *Clin Ther*. 2006; **28**(11): 1882-1891.
11. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? *Am J Psychiatry*. 2000; **157**(9): 1501-1504.
12. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. *Arch Gen Psychiatry*. 2000; **57**(4): 375-380.

13. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR\*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. *Psychiatr Serv*. 2009; **60**(11): 1439-1445.
14. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. *Arch Gen Psychiatry*. 1991; **48**(9): 851-855.
15. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. *Psychol Med*. 2011; **41**(6): 1165-1174.
16. Mojtabai R. Residual symptoms and impairment in major depression in the community. *Am J Psychiatry*. 2001; **158**(10): 1645-1651.
17. Zimmerman M, Posternak MA, Chelminski I. Using a self-report depression scale to identify remission in depressed outpatients. *Am J Psychiatry*. 2004; **161**(10): 1911-1913.
18. Trivedi MH, Morris DW, Wisniewski SR, et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. *Am J Psychiatry*. 2013; **170**(6): 633-641.
19. McIntyre RS. Using measurement strategies to identify and monitor residual symptoms. *J Clin Psychiatry*. 2013; **74**(Suppl 2): 14-18.
20. McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. *Depress Anxiety*. 2013; **30**(6): 515-527.
21. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. *Lancet*. 2009; **374**(9690): 609-619.
22. Harding KJ, Rush AJ, Arbuckle M, Trivedi MH, Pincus HA. Measurement-based care in psychiatric practice: a policy framework for implementation. *J Clin Psychiatry*. 2011; **72**(8): 1136-1143.
23. McIntyre RS, Konarski JZ, Gupta S. Editorial: sharpening the focus in mood disorders: from disease models to individualized measurement-based care. *Ann Clin Psychiatry*. 2007; **19**(4): 213-214.
24. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: implications for clinical practice. *Am J Psychiatry*. 2006; **163**(1): 28-40.
25. Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. *Can J Psychiatry*. 2012; **57**(12): 782-788.
26. Szegedi A, Jansen WT, Van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. *J Clin Psychiatry*. 2009; **70**(3): 344-353.
27. Harmer CJ, O'Sullivan U, Favaron E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. *Am J Psychiatry*. 2009; **166**(10): 1178-1184.
28. Uher R, Mors O, Rietschel M, et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. *J Clin Psychiatry*. 2011; **72**(11): 1478-1484.
29. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. *J Affect Disord*. 2009; **117**(Suppl 1): S26-S43.
30. Arnow BA, Blasey C, Williams LM, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D Trial. *Am J Psychiatry*. 2015; **172**(8): 743-750.
31. Schatzberg AF, DeBattista C, Lazzaroni LC, Etkin A, Murphy GM Jr, Williams LM. ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D Trial. *Am J Psychiatry*. 2015; **172**(8): 751-759.
32. Gelenberg AJ. A review of the current guidelines for depression treatment. *J Clin Psychiatry*. 2010; **71**(7): e15.
33. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\*D report. *Am J Psychiatry*. 2006; **163**(11): 1905-1917.
34. Han C, Wang SM, Kwak KP, et al. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study. *J Psychiatr Res*. 2015; **66-67**: 84-94.
35. Nelson JC, Rahman Z, Laubmeier KK, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. *CNS Spectr*. 2014; **19**(6): 528-534.
36. Nelson JC, Thase ME, Bellocchio EE, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. *Int Clin Psychopharmacol*. 2012; **27**(3): 125-133.
37. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. *Am J Psychiatry*. 2009; **166**(9): 980-991.
38. Zhou X, Keitner GI, Qin BM, et al. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. *Int J Neuropsychopharmacol*. 2015; **18**(11): pyv060.
39. McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDA-approved treatment options in bipolar depression. *CNS Spectr*. 2013; **18**(Suppl 1): 4-20.
40. Citrome L. Brexpiprazole: a new dopamine D2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder. *Drugs Today (Barc)*. 2015; **51**(7): 397-414.
41. Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. *J Clin Psychiatry*. 2014; **75**(2): 169-177.
42. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. *J Clin Psychiatry*. 2002; **63**(3): 181-186.
43. Cooper JA, Tucker VL, Papakostas GI. Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. *J Psychopharmacol*. 2014; **28**(2): 118-124.
44. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? *Neurotoxicology*. 2009; **30**(4): 497-521.
45. Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. *Support Care Cancer*. 2001; **9**(6): 469-470.
46. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. *Am J Psychiatry*. 2010; **167**(3): 281-288.
47. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. *Am J Psychiatry*. 2011; **168**(7): 689-701.
48. Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major

- depressive disorder: results of a double-blind, randomized, placebo-controlled trial. *J Clin Psychiatry*. 2008; **69**(1): 87-94.
49. Lavretsky H, Reinlieb M St, Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial 1. *Am J Psychiatry*. 2015; **172**(6): 561-569.
  50. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. *J Clin Psychiatry*. 2003; **64**(9): 1057-1064.
  51. Rizvi SJ, Geraci J, Ravindran A, Kennedy SH. Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue. *J Clin Psychopharmacol*. 2014; **34**(6): 755-759.
  52. Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. *J Clin Psychiatry*. 2015; **76**(4): e487-e498.
  53. Hollon SD, DeRubeis RJ, Fawcett J, et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. *JAMA Psychiatry*. 2014; **71**(10): 1157-1164.
  54. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. *Arch Gen Psychiatry*. 2005; **62**(4): 409-416.
  55. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. *JAMA*. 2010; **303**(1): 47-53.
  56. Hollon SD, Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. *Depress Anxiety*. 2010; **27**(10): 891-932.
  57. Hirschfeld RM, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. *Biol Psychiatry*. 2002; **51**(2): 123-133.
  58. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR\*D report. *Am J Psychiatry*. 2007; **164**(5): 739-752.
  59. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. *J ECT*. 2004; **20**(1): 13-20.
  60. Kellner CH, Greenberg RM, Murrrough JW, Bryson EO, Briggs MC, Pasculli RM. ECT in treatment-resistant depression. *Am J Psychiatry*. 2012; **169**(12): 1238-1244.
  61. Schulze-Rauschenbach SC, Harms U, Schlaepfer TE, Maier W, Falkai P, Wagner M. Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. *Br J Psychiatry*. 2005; **186**(5): 410-416.
  62. Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. *Biol Psychiatry*. 2003; **53**(4): 324-331.
  63. Grunhaus L, Dannon PN, Schreiber S, et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. *Biol Psychiatry*. 2000; **47**(4): 314-324.
  64. Rasmussen KG. Some considerations in choosing electroconvulsive therapy versus transcranial magnetic stimulation for depression. *J ECT*. 2011; **27**(1): 51-54.
  65. Kennedy SH, Giacobbe P. Treatment resistant depression—advances in somatic therapies. *Ann Clin Psychiatry*. 2007; **19**(4): 279-287.
  66. Thachil AF, Mohan R, Bhugra D. The evidence base of complementary and alternative therapies in depression. *J Affect Disord*. 2007; **97**(1-3): 23-35.
  67. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAME) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. *Am J Psychiatry*. 2010; **167**(8): 942-948.
  68. Papakostas GI, Shelton RC, Zajecka JM, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. *Am J Psychiatry*. 2012; **169**(12): 1267-1274.
  69. Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. *PLoS One*. 2014; **9**(5): e96905.
  70. Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. *J Clin Psychiatry*. 2015; **76**(3): 247-252.
  71. Aligeti S, Quinones M, Salazar R. Rapid resolution of suicidal behavior and depression with single low-dose ketamine intravenous push even after 6 months of follow-up. *J Clin Psychopharmacol*. 2014; **34**(4): 533-535.
  72. Diazgranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. *J Clin Psychiatry*. 2010; **71**(12): 1605-1611.
  73. Price RB, Iosifescu DV, Murrrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. *Depress Anxiety*. 2014; **31**(4): 335-343.
  74. Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. *Annu Rev Pharmacol Toxicol*. 2014; **54**: 119-139.
  75. Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. *Transl Psychiatry*. 2015; **5**: e632.
  76. Pots WT, Fledderus M, Meulenbeek PA, Ten Klooster PM, Schreurs KM, Bohlmeijer ET. Acceptance and commitment therapy as a web-based intervention for depressive symptoms: randomised controlled trial. *Br J Psychiatry* In press. DOI: 10.1192/bjp.bp.114.146068.
  77. Kelders SM, Bohlmeijer ET, Pots WT, van Gemert-Pijnen JE. Comparing human and automated support for depression: Fractional factorial randomized controlled trial. *Behav Res Ther*. 2015; **72**: 72-80.
  78. Renton T, Tang H, Ennis N, et al. Web-based intervention programs for depression: a scoping review and evaluation. *J Med Internet Res*. 2014; **16**(9): e209.
  79. IsHak WW, Mirocha J, Pi S, et al. Patient-reported outcomes before and after treatment of major depressive disorder. *Dialogues Clin Neurosci*. 2014; **16**(2): 171-183.
  80. Papakostas GI. Components of cognitive functioning and their measurement. *J Clin Psychiatry*. 2015; **76**(6): e16.
  81. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. *Psychiatry Res*. 2006; **145**(1): 39-48.

82. Buist-Bouwman MA, Ormel J, de Graaf R, *et al.* Mediators of the association between depression and role functioning. *Acta Psychiatr Scand.* 2008; **118**(6): 451-458.
83. McIntyre RS, Soczynska JZ, Woldeyohannes HO, *et al.* The impact of cognitive impairment on perceived workforce performance: Results from the International Mood Disorders Collaborative Project. *Compr Psychiatry.* 2015; **56**: 279-282.
84. McIntyre RS, Xiao HX, Syeda K, *et al.* The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. *CNS Drugs.* 2015; **29**(7): 577-589.
85. Insel TR. The NIMH Research Domain Criteria (RDoC) project: precision medicine for psychiatry. *Am J Psychiatry.* 2014; **171**(4): 395-397.
86. Insel T, Cuthbert B, Garvey M, *et al.* Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. *Am J Psychiatry.* 2010; **167**(7): 748-751.
87. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. *Int J Neuropsychopharmacol.* 2014; **17**(10): 1557-1567.
88. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. *Int J Neuropsychopharmacol* In press. DOI: 10.1093/ijnp/pyv082.
89. Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. *Expert Opin Drug Saf.* 2015; **14**(8): 1291-1304.
90. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. *Int Clin Psychopharmacol.* 2012; **27**(4): 215-223.
91. Raskin J, Wiltse CG, Siegal A, *et al.* Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. *Am J Psychiatry.* 2007; **164**(6): 900-909.
92. Madhoo M, Keefe RS, Roth RM, *et al.* Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. *Neuropsychopharmacology.* 2014; **39**(6): 1388-1398.
93. Moskal JR, Burch R, Burgdorf JS, *et al.* GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. *Expert Opin Investig Drugs.* 2014; **23**(2): 243-254.
94. Lennox R, Porter DW, Flatt PR, Holscher C, Irwin N, Gault VA. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. *Neuropharmacology.* 2014; **86**: 22-30.
95. McIntyre RS, Powell AM, Kaidanovich-Beilin O, *et al.* The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. *Behav Brain Res.* 2013; **237**: 164-171.
96. Goldstein BI, Carnethon MR, Matthews KA, *et al.* Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. *Circulation* In press. DOI: 10.1161/CIR.0000000000000229.
97. Liu CS, Carvalho AF, Mansur RB, McIntyre RS. Obesity and bipolar disorder: synergistic neurotoxic effects? *Adv Ther.* 2013; **30**(11): 987-1006.
98. Lin CH, Chen CC, Wong J, McIntyre RS. Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. *J Affect Disord.* 2014; **161**: 123-126.
99. Rizvi SJ, Grima E, Tan M, *et al.* Treatment-resistant depression in primary care across Canada. *Can J Psychiatry.* 2014; **59**(7): 349-357.
100. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. *Lancet.* 2012; **379**(9833): 2291-2299.
101. Nierenberg AA, Sylvia L, Doederlein A, *et al.* Improving the care of patients who have treatment-resistant depression: the promise of the PCORnet Mood Network. *J Clin Psychiatry.* 2015; **76**(4): e528-e530.
102. Kucyi A, Alsuwaidan MT, Liauw SS, McIntyre RS. Aerobic physical exercise as a possible treatment for neurocognitive dysfunction in bipolar disorder. *Postgrad Med.* 2010; **122**(6): 107-116.
103. Masley S, Roetzheim R, Gualtieri T. Aerobic exercise enhances cognitive flexibility. *J Clin Psychol Med Settings.* 2009; **16**(2): 186-193.
104. Davis CL, Tomporowski PD, Boyle CA, *et al.* Effects of aerobic exercise on overweight children's cognitive functioning: a randomized controlled trial. *Res Q Exerc Sport.* 2007; **78**(5): 510-519.
105. Kubesch S, Bretschneider V, Freudenmann R, *et al.* Aerobic endurance exercise improves executive functions in depressed patients. *J Clin Psychiatry.* 2003; **64**(9): 1005-1012.
106. Shay KA, Roth DL. Association between aerobic fitness and visuospatial performance in healthy older adults. *Psychol Aging.* 1992; **7**(1): 15-24.
107. Shelton RC, Trivedi MH. Using algorithms and computerized decision support systems to treat major depression. *J Clin Psychiatry.* 2011; **72**(12): e36.

## Optional CME Posttest and Certificate

*CME Credit Expires: November 30, 2018*

### CME Posttest Study Guide

**NOTE: The posttest can only be submitted online.** The below posttest questions have been provided solely as a study tool to prepare for your online submission. **Faxed/mailed copies of the posttest cannot be processed** and will be returned to the sender. If you do not have access to a computer, contact NEI customer service at 888-535-5600.

1. A 28-year-old woman presents with symptoms of depressed mood, executive dysfunction, and anxiety. What symptom dimension/domain is most associated with functional outcomes in major depressive disorder?
  - A. Anxiety
  - B. Cognition
  - C. Mood
2. A recent meta-analysis of adjunctive treatments for depression found that which of the following significantly reduced depressive symptoms with the most robust improvement in treatment-resistant major depressive disorder?
  - A. Buspirone
  - B. Methylphenidate
  - C. Modafinil
  - D. Quetiapine
3. The evidence base regarding combining antidepressants at the outset of treatment to enhance/accelerate treatment outcomes is:
  - A. Positive
  - B. Negative
  - C. Inconsistent
4. A 23-year-old patient with depression has experienced partial response and wants to attempt augmentation with a complementary/alternative medicine (CAM). Which of the following has the LEAST evidence to support efficacy in depression?
  - A. L-methylfolate
  - B. S-adenosyl methionine (SAMe)
  - C. Omega-3

### CME Online Posttest and Certificate Instructions

There is no posttest fee nor fee for CME credits.

1. Read the article, evaluating the content presented
2. Complete the posttest and activity evaluation, available only online at [www.neiglobal.com/CME](http://www.neiglobal.com/CME) (under “CNS Spectrums”)
3. Print your certificate, if a score of 70% or more is achieved

Questions? call 888-535-5600, or email [CustomerService@neiglobal.com](mailto:CustomerService@neiglobal.com)

**Posttest & Evaluation**